Clinical data | |
---|---|
Other names | AET; Androst-5-ene-3β,7β,17β-triol; β-Androstenetriol; β-AET |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C19H30O3 |
Molar mass | 306.446 g·mol−1 |
3D model (JSmol) | |
| |
|
Androstenetriol (AET, androst-5-ene-3β,7β,17β-triol, β-androstenetriol, or β-AET) is a steroid produced in the adrenal glands as a metabolite of dehydroepiandrosterone (DHEA).[1] It is believed to have similar effects as DHEA and androstenediol.[2] A study in rodents found that the compound was a weak androgen and estrogen, but did not bind to the androgen, estrogen, progesterone, or glucocorticoid receptors.[1] Synthetic analogues of androstenetriol such as bezisterim (HE3286, NE3107; the 17α-ethynylated derivative) have been developed and are under study.[3][4][5]
Bezisterim, a derivative of the natural anti-inflammatory steroid β-AET, is an orally active NF-κB inhibitor. It has been shown to protect neurons by reducing inflammation and improving glucose utilization, thereby promoting brain health. Clinical results have demonstrated that bezisterim can improve cognition and biomarker levels in AD patients and is currently in phase III clinical trials [68].